BTK Inhibitors and CAR T-Cell Therapy in Treating Mantle Cell Lymphoma-Finding a Dancing Partner

Area of Science:

• Hematology
• Oncology
• Immunotherapy

Background:

• Relapsed or refractory mantle cell lymphoma (R/R MCL) treatment has been transformed by Bruton's tyrosine kinase (BTK) inhibitors and chimeric antigen receptor (CAR) T-cell therapy.
• Approved BTK inhibitors for R/R MCL include ibrutinib, acalabrutinib, and zanubrutinib.
• Brexucabtagene autoleucel is an approved CAR T-cell therapy for R/R MCL, demonstrating efficacy in the ZUMA-2 trial.

Purpose of the Study:

• To review the feasibility of combining BTK inhibitors (BTKis) with CAR T-cell therapy for R/R MCL.
• To explore potential combination treatment scenarios for R/R MCL.
• To evaluate the potential benefits of combination strategies as these therapies become standard.

Main Methods:

• Review of current literature on BTK inhibitors and CAR T-cell therapy in R/R MCL.
• Analysis of existing evidence for combined treatment efficacy.
• Presentation of potential combination treatment scenarios.

Main Results:

• BTKis and CAR T-cell therapy represent significant advancements in R/R MCL treatment.
• Evidence suggests that combining BTKis with CAR T-cell therapy may enhance CAR T-cell efficacy.
• Combination strategies warrant evaluation for improved outcomes in R/R MCL.

Conclusions:

• Combination of BTK inhibitors and CAR T-cell therapy is a feasible strategy for R/R MCL.
• Further evaluation of combination treatment is crucial as these therapies become standard care.
• Optimizing combination strategies may improve patient outcomes in R/R MCL.